Pilot Randomized Trial of Blue-Blocking Glasses for Treating Sleep Disorders in Child and Adolescent Psychiatry
Led by Helse Fonna · Updated on 2026-09-18
40
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Sleep problems such as insomnia and delayed sleep-wake phase disorder are common in children and adolescents receiving psychiatric care. These issues can worsen psychiatric conditions and lead to chronic disorders. This research evaluates the use of blue-blocking glasses or real darkness as an additional treatment to improve sleep and circadian rhythms in young patients, aiming to reduce reliance on medications and support healthier sleep patterns.
Participants are randomly assigned to one of two groups one group uses blue-blocking glasses or real darkness from 9 p.m. until their desired wake-up time along with a dark mode setting on their mobile phone the other group uses only the dark mode setting on their mobile phone. Both groups continue with their usual treatment. The study monitors effects after 1 week, with outpatients also evaluated after 2 weeks.
During the study, participants undergo various assessments including sleep onset latency measurements, melatonin production tests, and questionnaires on mood and anxiety. Activity is tracked using biosensors. Researchers will analyze changes from baseline to understand the interventions impact on sleep, emotional reactivity, and overall well-being. The pilot aims to gather data to support larger future studies and improve hospital sleep environments for young patients.
CONDITIONS
Brief Title
Blue-blocking Glasses for Sleep Disorders in Child and Adolescent Psychiatry
Research Team
T
Tone Elise G Henriksen, MD PhD
M
Marit Nymoen, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Age 12 to 18 years, receiving care from child and adolescent mental health services at specified hospitals
Current insomnia or delayed sleep phase disorder with psychiatric symptoms or diagnoses
Able and willing to provide written informed consent
Participants aged 12 to under 16 need consent from both parents or carers
Able to follow study procedures
Able to stop melatonin or blue-blocking glasses use with at least 3 days washout before study
You will not qualify if you...
Unable to comply with study procedures for at least one night
Blindness or severe eye translucency reduction in both eyes
Known malformation or damage of optical tract causing blindness
Use of melatonin formulas that cannot be paused
High risk for suicide or self-harm
Unlikely to obtain consent from both parents or carers for participants aged 12 to under 16
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 1 to 2 weeks
Participants use blue-blocking glasses or real darkness from 9 p.m. to wake-up time along with a phone dark mode setting, or only use the phone dark mode setting, while continuing usual care.
Regular assessments during intervention period
Follow-up
Duration - Up to 2 weeks for outpatients
Researchers assess sleep onset latency, melatonin production, mood, anxiety, and activity through questionnaires and biosensors to evaluate treatment effects.
Follow-up assessments after treatment period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 40 Hz Flicker Light Therapy for Insomnia and Sleep Problems in Parkinsons Disease Patients Aged 50 to 75
Study of Lemborexant Versus Placebo to Reduce Brain Biomarkers in Adults Aged 40-65 With Insomnia Disorder
Comparing Tele-Brief Behavioral Treatment and Tele-Cognitive-Behavioral Therapy for Insomnia in Socioeconomically Disadvantaged Adults in Primary Care
Observational Study Evaluating Lemborexant for Insomnia in Adults With Psychiatric Disorders
Study Comparing Inhaled and Oral Melatonin for Treating Insomnia in Adults Aged 55 and Older
Comparing Common Prescription and Over-the-Counter Medications for Insomnia Treatment in Adults Using a Sequential Randomized Trial Design
Evaluating a Stepped Care Approach to Deliver Cognitive Behavioral Therapy for Insomnia in Adults Aged 18 to 70 in Community Settings
Improving Sleep and Reducing Sedentary Time in Adults with Type 2 Diabetes
A 12-Week Study Using CBTi and Behavior Change Support
Evaluating Suvorexant for Insomnia in Adults With Opioid Use Disorder A Randomized, Placebo-Controlled Phase 3 Study
Randomized Trial of Accelerated Behavioral Therapies Combining Cognitive-Behavioral and Written Exposure Treatments for Military-Related Insomnia, Nightmares, and PTSD
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical benefits of modifying the evening light environment in an acute psychiatric unit: A single-centre, two-arm, parallel-group, pragmatic effectiveness randomised controlled trial.
Håvard Kallestad, Knut Langsrud, Melanie Rae Simpson...